The Lenovo IdeaPad Pro 5i is powered by Intel's top Arrow Lake-H processor, the Core Ultra 9 285H, features a gorgeous ...

The IdeaPad ... Perhaps Lenovo wanted to give the small fingerprint scanner below the arrow keys a lot of breathing room. I'd much rather move the fingerprint reader to the power button where ...

The $750 IdeaPad 5x 2-in-1 from Lenovo is another great Snapdragon X laptop, this time powered by the entry-level X Plus ...

You’re not going to be wowed by the Lenovo IdeaPad Slim 3. But, if you’re looking for a laptop that’s “good enough,” a phrase ...

Novo Nordisk announced phase 1b/2a clinical trial results for amycretin this morning. Patients taking the GLP-1 drug lost an average of 9.7% of their weight in 36 weeks. This is the best news Novo ...

Novo Nordisk has reported 22% weight loss in people who received weekly amycretin injections for 36 weeks, triggering an 11% jump in the Danish drugmaker’s share price in premarket trading.

Novo Nordisk A/S rose the most since August 2023 after its experimental shot delivered as much as 22% weight loss in an early-stage trial, boosting investors’ hopes for the drugmaker’s pipeline.

Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it gave to pharmacy firms, obesity charities and other professional bodies ...

Novo Nordisk shares rose sharply Friday after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients lose 22% of their body weight in a clinical trial. Shares were 7 ...

Patients to pay no more than $35 a month Eli Lilly, Sanofi previously settled overcharging claims Novo Nordisk denies wrongdoing, pledges affordable insulin Jan 27 (Reuters) - Novo Nordisk (NOVOb ...

Results of early-stage trial of injectable amycretin Novo shares jump as much as 13% to a one-month high Novo faces strong competition in obesity drugs from Eli Lilly Jan 24 (Reuters ...